NATIONAL INSTITUTES OF HEALTH

Conditions: Acinar Cell Carcinoma
Adenoid Cystic Carcinoma
Adrenal Cortical Carcinoma
Adrenal Gland Pheochromocytoma
Anal Canal Neuroendocrine Carcinoma
Anal Canal Undifferentiated Carcinoma
Angiosarcoma
Apocrine Neoplasm
Appendix Mucinous Adenocarcinoma
Bartholin Gland Transitional Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography Test
Biological: Ipilimumab
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab

First Posted Date: 2016-07-15

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 818

Registration Number: NCT02834013

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States

and more 1006 locations

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Phase 1

Recruiting

Conditions: Renal Cell Cancer
Breast Cancer
Melanoma
Pancreatic Cancer
Ovarian Cancer

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Aldesleukin
Biological: Anti-hCD70 CAR transduced PBL

First Posted Date: 2016-07-13

Last Posted Date: 2025-05-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 124

Registration Number: NCT02830724

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Evaluation of Adults With Endocrine and Metabolic-Related Conditions

Recruiting

Conditions: Endocrine Diseases

First Posted Date: 2016-07-12

Last Posted Date: 2025-06-05

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 1250

Registration Number: NCT02830308

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Differential Influences of Integral and Incidental Emotion on Cancer-related Judgments and Decision Making

Completed

Conditions: Overweight
Obesity
Cancer

First Posted Date: 2016-07-12

Last Posted Date: 2020-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6242

Registration Number: NCT02829554

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

Phase 2

Completed

Conditions: B Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia
Acute Leukemia of Ambiguous Lineage

Interventions: Drug: Azacitidine
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin
Drug: Daunorubicin Hydrochloride
Drug: Dexamethasone
Procedure: Echocardiography
Drug: Hydrocortisone Sodium Succinate
Drug: Leucovorin
Drug: Leucovorin Calcium
Procedure: Magnetic Resonance Imaging
Drug: Mercaptopurine
Drug: Methotrexate
Procedure: Multigated Acquisition Scan
Drug: Pegaspargase
Drug: Prednisolone
Drug: Thioguanine
Drug: Vincristine
Drug: Vincristine Sulfate

First Posted Date: 2016-07-11

Last Posted Date: 2025-02-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 78

Registration Number: NCT02828358

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 167 locations

Collection of Peripheral Blood Mononuclear Cells (PBMCs) From Healthy People for the Expansion of T Cells for Adoptive Cell Therapy

Recruiting

Conditions: Healthy Volunteer

First Posted Date: 2016-07-04

Last Posted Date: 2025-03-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 500

Registration Number: NCT02821806

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Phase 2

Completed

Conditions: Bile Duct Cancer
Biliary Tract Neoplasms
Hepatocellular Carcinoma
Cholangiocarcinoma
Liver Cancer

Interventions: Drug: Durvalumab
Drug: Tremelimumab
Procedure: Cryoablation
Procedure: Trans-arterial Catheter Chemoembolization (TACE)
Procedure: Radiofrequency Ablation (RFA)

First Posted Date: 2016-07-04

Last Posted Date: 2023-03-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT02821754

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Collection of Tissue Blocks or Slides From Patients With Cancer

Completed

Conditions: Carcinogens
Neoplasm, Benign
Benign Neoplasms
Cancer
Tumor

First Posted Date: 2016-06-23

Last Posted Date: 2024-10-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 191

Registration Number: NCT02810405

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Home Terms & Conditions Privacy Policy